Consolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care

Transl Lung Cancer Res. 2024 Oct 31;13(10):2853-2855. doi: 10.21037/tlcr-24-540. Epub 2024 Oct 28.

Authors

Fang Wu^{1

2}, Yue Zeng¹, Joel W Neal²

Affiliations

¹ Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
² Division of Oncology, Department of Medicine, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, USA.

No abstract available

Keywords: LAURA; Non-small cell lung cancer (NSCLC); consolidation; epidermal growth factor receptor (EGFR); osimertinib.

Publication types

Editorial
Comment